Phase I study for poor-prognosis lymphoma: Augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation - A preliminary report

Seminars in Oncology

Volumn 31, Issue SUPPL. 18, 2004, Pages 59-61

  Phillips II, G L ^a   Abboud, C N ^a   Bernstein, S H ^a   Friedberg, J W ^a   Ifthikharuddin, J J ^a   Lancet, J E ^a   Liesveld, J L ^a   Spreng, E ^a   Johnson, V ^b   Chapman, M ^b   Vesole, D H ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ADVANCED CANCER; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CELL PROTECTION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT;

EID: 13844252053     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.12.014     Document Type: Conference Paper

References (13)

1. S.A. Mink, J.O. Armitage High-dose therapy in lymphomas A review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma Onocologist 6 2001 247 256
2. T. Philip, J.O. Armitage, G. Spitzer High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma N Engl J Med 316 1987 1493
3. P.J. Bierman, J.W. Sweetenham, F.R. Loberiza Jr Syngeneic hematopoietic stem-cell transplantation for non-Hodgkins lymphoma A comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation J Clin Oncol 21 2003 3744 3753 (Epub 2003 Sep)
4. A. Salar, J. Sierra, M. Gandarillas Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma The role of preparative regimens Bone Marrow Transplant 27 2001 405 412
5. T. Philip, P. Biron, D. Maraninchi Role of massive chemotherapy and autologous bone-marrow transplantation in non-Hodgkin's malignant lymphoma Lancet 1 1984 391
6. G.L. Phillips, B. Meisenberg, D.E. Reece Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan A phase I study Biol Blood Marrow Transplant 10 2004 473 483
7. S.I. Bearman, F.R. Appelbaum, C.D. Buckner Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 6 1988 1562 1568
8. 2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma Bone Marrow Transplant 33 2004 781 787
9. 2 plus amifostine cytoprotection and autologous stem cell transplantation in multiple myeloma patients Blood 98 2001 196 (abstr 822)
10. H.M. Lazarus, R.H. Herzig, J. Graham-Pole Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer J Clin Oncol 1 1983 359 367
11. S.N. Wolff, R.H. Herzig, J.W. Fay High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma Results of phase I and II studies of the North American Bone Marrow Transplantation Group J Clin Oncol 7 1989 245 249
12. E. Jantunen, T. Kuittinen, T. Nousianinen BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy Leuk Lymphoma 44 2003 1151 1158
13. W. Mills, J. Strang, A.H. Goldstone Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma Leuk Lymphoma 17 1995 263 270